| Year |
Title |
Altmetric |
| 2020
|
Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.
Cancer Gene Therapy.
27:898-909.
2020
|
|
| 2020
|
Dual-targeted extracellular vesicles to facilitate combined therapies for neuroendocrine cancer treatment
2020
|
|
| 2020
|
Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells.
Molecules.
25.
2020
|
|
| 2020
|
Cytochrome P4501B1 in bone marrow is co-expressed with key markers of mesenchymal stem cells. BMS2 cell line models PAH disruption of bone marrow niche development functions.
Toxicology and Applied Pharmacology.
401.
2020
|
|
| 2020
|
Phosphoprotein-based biomarkers as predictors for cancer therapy
2020
|
|
| 2020
|
A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor–guided antibody-drug conjugate: Perspectives on clinical response?.
Surgery.
167:197-203.
2020
|
|
| 2020
|
Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy.
Cancer Gene Therapy.
2020
|
|
| 2020
|
Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance
2020
|
|
| 2020
|
Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Surgery.
167:189-196.
2020
|
|
| 2020
|
Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and Validation.
Biotechnology Journal.
15.
2020
|
|
| 2019
|
Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitors.
Cancers.
11.
2019
|
|
| 2019
|
Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers.
Surgery.
165:64-68.
2019
|
|
| 2018
|
Bioprocess development of antibody-drug conjugate production for cancer treatment.
PLoS ONE.
13.
2018
|
|
| 2018
|
Notch3 as a novel therapeutic target in metastatic medullary thyroid cancer.
Surgery.
163:104-111.
2018
|
|
| 2017
|
Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1.
Cancer Medicine.
6:2142-2152.
2017
|
|
| 2017
|
Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis.
Cancer.
123:769-782.
2017
|
|
| 2017
|
Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging
2017
|
|
| 2017
|
AB3-loaded and tumor-targeted unimolecular micelles for medullary thyroid cancer treatment.
Journal of Materials Chemistry B.
5:151-159.
2017
|
|
| 2017
|
Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo.
Oncotarget.
8:70828-70840.
2017
|
|
| 2016
|
KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.
Biomaterials.
97:22-33.
2016
|
|
| 2016
|
Notch1 signaling regulates the aggressiveness of differentiated thyroid cancer and inhibits SERPINE1 expression.
Clinical Cancer Research.
22:3582-3592.
2016
|
|
| 2016
|
Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy.
Biomaterials.
91:1-10.
2016
|
|
| 2015
|
Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.
Cancer Gene Therapy.
22:496-505.
2015
|
|
| 2015
|
Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.
Cancer Gene Therapy.
22:410-416.
2015
|
|
| 2015
|
Tumor-suppressor role of notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction.
Molecular Cancer Therapeutics.
14:499-512.
2015
|
|
| 2014
|
Hesperetin Activates the Notch1 Signaling Cascade, Causes Apoptosis, and Induces Cellular Differentiation in Anaplastic Thyroid Cancer.
Annals of Surgical Oncology.
21:497-504.
2014
|
|
| 2014
|
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Journal of Surgical Research.
190:191-197.
2014
|
|
| 2014
|
Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo.
Cancer Gene Therapy.
21:518-525.
2014
|
|
| 2013
|
Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy.
Nanoscale.
5:9924-9933.
2013
|
|
| 2013
|
Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.
Molecular Cancer Therapeutics.
12:1276-1287.
2013
|
|
| 2013
|
Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo.
Cancer.
119:774-781.
2013
|
|
| 2013
|
Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch
2013
|
|
| 2013
|
Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.
Cancer Medicine.
2:734-743.
2013
|
|
| 2012
|
Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.
Nanoscale.
4:7185-7193.
2012
|
|
| 2011
|
Expression of the active notch1 decreases MTC tumor growth in vivo.
Journal of Surgical Research.
171:23-27.
2011
|
|
| 2011
|
Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines.
Gynecologic Oncology.
122:396-401.
2011
|
|
| 2011
|
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
2011
|
|
| 2011
|
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.
Cancer.
117:1386-1398.
2011
|
|
| 2010
|
Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.
Molecular Cancer Therapeutics.
9:429-437.
2010
|
|
| 2008
|
Suberoyl bishydroxamic acid activates Notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Annals of Surgical Oncology.
15:2600-2605.
2008
|
|
| 2007
|
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.
Journal of Gastrointestinal Surgery.
11:1515-1520.
2007
|
|
| 2007
|
Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells
2007
|
|
| 2005
|
Reduced DNA repair capacity in laryngeal cancer subjects: A comparison of phenotypic and genotypic results
2005
|
|
| 2003
|
Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liver.
Toxicology and Applied Pharmacology.
193:84-96.
2003
|
|
| 2001
|
Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk
2001
|
|
| 2000
|
Polymorphism in detoxifying enzymes.
Postepy biochemii.
46:50-59.
2000
|
|
| 1999
|
DNA copy number losses are more frequent in primary larynx tumors with lymph node metastases than in tumors without metastases.
Cancer Genetics.
114:31-34.
1999
|
|
| 1999
|
Molecular and cellular alterations in tobacco smoke-associated larynx cancer
1999
|
|
| 1998
|
Glutathione S-transferase M1 and T1 genotypes and susceptibility to smoking related larynx cancer.
Biomarkers.
3:149-155.
1998
|
|
